Doyle, who was previously COO at Peakdale, has led UK support drug discovery and development company Concept Life Sciences through a significant growth phase during the past two years.
He combines sound business acumen with an impressive scientific record, having authored more than 50 peer reviewed papers and most recently co-edited a Royal Society of Chemistry two-volume set on Synthetic Methods in Drug Discovery.
Doyle, a bio-organic chemistry DPhil, began his career at the Wellcome Foundation working across a wide variety of discovery programmes.
Following the Glaxo merger, Doyle left Wellcome to establish one of the UK’s first CROs, Biofocus.
Doyle then joined Peakdale, as Technical Director, in 2008 and was promoted to COO in 2010, maintaining that post following the Concept Life Sciences’ acquisition.
Michael Fort, Concept’s Executive Chairman said:
“Paul has done a sterling job at leading us through our ambitious growth programme during the last two years and we look forward to him helping drive our exciting expansion plans during 2017”.
